Developer docs
API playgroundTry for free, no card

Search company profiles

Apogee Therapeutics

Full company profile

uuid00002l6

Namestring
Apogee Therapeutics
Legal namestring
Apogee Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Apogee Therapeutics is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. Founded in 2022 as a spinout from Paragon Therapeutics and led by veterans of BridgeBio, the company went public on NASDAQ under ticker APGE in December 2024 and is headquartered in Waltham, Massachusetts with an additional office in San Francisco. Its pipeline is anchored by zumilokibart (formerly APG777), a subcutaneous half-life extended monoclonal antibody targeting IL-13 that has generated positive Phase 2 Part B 16-week data in moderate-to-severe atopic dermatitis (approximately two-thirds of patients achieving significant skin clearance at 16 weeks) and is also being advanced in asthma and eosinophilic esophagitis. The pipeline additionally includes combination programs APG279 (IL-13 plus OX40L) and APG273 (IL-13 plus TSLP), as well as APG808 targeting IL-4Rα, all leveraging the company's shared antibody engineering platform.

Apogee's underlying technology is an FcRn-mediated half-life extension platform that engineers antibodies to bind better to the neonatal Fc receptor, sparing them from degradation and enabling subcutaneous dosing every three to six months versus the bi-weekly or monthly dosing typical of current standard-of-care biologics such as Dupixent. The company has executed a 'pipeline-in-a-product' strategy, applying the lead asset across multiple I&I indications and pursuing both monotherapy and combination approaches to broaden inflammation coverage. Clinical development currently spans the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

As a pre-revenue biotech, Apogee generates no product sales. Its business model depends on future commercialization through traditional pharmaceutical distribution and field sales teams targeting dermatologists, pulmonologists, and gastroenterologists, supported by a newly appointed Chief Commercial Officer. To date the company has financed operations primarily through capital markets: a $149M Series B (December 2022), a $483M upsized public offering (March 2024), a $345M public offering (October 2025), a $403M public offering (March 2026), and a strategic financing collaboration with Blackstone Life Sciences worth up to $1.3 billion (May 2026). In June 2026, AbbVie announced a definitive agreement to acquire Apogee for approximately $10.9 billion in cash, expected to close in Q3 2026 subject to shareholder and regulatory approvals.

Short descriptiontext

Apogee Therapeutics is a clinical-stage biotechnology company developing half-life extended monoclonal antibodies for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Founded in 2022 as a Paragon Therapeutics spinout, the company went public on NASDAQ in 2024 and is subject to a pending AbbVie acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, monoclonal antibody therapeutics, inflammatory disease biologics, atopic dermatitis treatment, antibody engineering platform
Industry4 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics and monoclonal antibody therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development
TypeOne Time License
Description

Clinical-stage biotechnology company with no approved products or revenue. Developing novel biologic therapies for inflammatory and immunology conditions. Revenue will be generated through product sales following regulatory approval.

marketscreener.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Apogee Therapeutics is developing a pipeline of novel, subcutaneous, half-life extended monoclonal antibody therapeutics targeting well-established immunology and inflammation pathways (IL-13, OX40L, TSLP, IL-4Rα) for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Its lead asset, Zumilokibart (APG777), targets IL-13 with dosing every 3-6 months versus bi-weekly dosing of standard-of-care biologics. The company is also advancing combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), plus APG808 (IL-4Rα).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 APEX Part B: Approximately two-thirds of patients achieved significant skin clearance at 16 weeks
+2 more records
Product overview1 text field

Apogee Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel antibody therapeutics for immunological and inflammatory diseases. The company's core product is Zumilokibart (APG777), a half-life extended monoclonal antibody targeting IL-13, which has completed Phase 2 for atopic dermatitis. The company is pursuing a 'pipeline-in-a-product' strategy with Zumilokibart across multiple indications including atopic dermatitis, asthma, and eosinophilic esophagitis. Additional programs include combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), as well as APG808 (IL-4Rα). All programs leverage advanced antibody engineering to optimize half-life and achieve less frequent dosing compared to existing treatments.

Product and service4 records
1Zumilokibart (APG777)
CategoryDrug Candidate
Description

Novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of atopic dermatitis (with positive Phase 2 Part B 16-week data), as well as asthma and eosinophilic esophagitis. Designed for subcutaneous dosing every 3 or 6 months versus bi-weekly dosing for current standard-of-care biologics.

2APG279
CategoryDrug Candidate
Description

Combination therapy comprising APG777 (zumilokibart) plus APG990, designed to address multiple immune signaling intervention points through dual inhibition of IL-13 and OX40L for potential first-in-class combination treatment in atopic dermatitis and other I&I indications.

3APG273
CategoryDrug Candidate
Description

Combination therapy comprising APG777 (zumilokibart) plus APG333, targeting IL-13 and TSLP for asthma and COPD, designed to address both central and local drivers of obstructive airway disease and potentially break through the efficacy ceiling observed with monotherapies.

4APG808
CategoryDrug Candidate
Description

Anti-IL-4Rα monoclonal antibody incorporating Apogee's half-life extension technology for the potential treatment of asthma, demonstrating safety and extended half-life in Phase 1 studies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2026-06-22
Description

AbbVie announced definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash ($135.11 per share). The acquisition aims to strengthen AbbVie's immunology portfolio with Apogee's pipeline including zumilokibart for atopic dermatitis and asthma. Deal expected to close Q3 2026 pending shareholder and regulatory approvals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-07
Description

Apogee acquired drug targets from Paragon Therapeutics at founding. Company spun out from Paragon with access to proprietary antibody engineering technology and targets.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology biotech focused on atopic dermatitis and other inflammatory skin diseases, directly overlapping with Apogee's lead AD indication and the same physician specialty channel.

TypeDirect peer
Description

Clinical-stage antibody developer focused on immunology and inflammation targets including IL-36, IL-33, and PD-1, with a comparable business model of developing novel mAbs for I&I indications.

TypeDirect peer
Description

Clinical-stage immunology company developing nanobody therapies for inflammatory skin and joint diseases, sharing Apogee's focus on differentiated biologics for I&I indications.

TypeDirect peer
Description

Clinical-stage biotech developing engineered antibodies for inflammatory bowel disease and other I&I indications, with overlapping leadership and a similar antibody-engineering platform approach.

TypeEmerging player
Description

Early-stage biotech developing novel biologics for autoimmune and inflammatory diseases, with a similar therapeutic-area focus to Apogee but earlier-stage pipeline assets.

TypeEmerging player
Description

Clinical-stage immunology company developing long-acting IL-23 antibodies for inflammatory skin diseases, sharing Apogee's half-life extension philosophy and AD indication focus.

TypeBroad incumbent
Description

Large biopharma and co-developer of Dupixent (the dominant AD biologic), making it the most direct commercial competitive incumbent to Apogee's lead asset.

TypeBroad incumbent
Description

Global biopharma developing lebrikizumab (anti-IL-13) and other immunology assets, a key head-to-head competitor referenced in Apogee's preclinical positioning.

TypeBroad incumbent
Description

Global biopharma and announced acquirer of Apogee; AbbVie's immunology franchise (Skyrizi, Rinvoq, Humira) provides the commercial engine that will deploy zumilokibart post-approval.

TypeOthers
Description

Antibody discovery platform company whose technology stack overlaps with Apogee's antibody engineering approach, though AbCellera operates as a discovery engine rather than a clinical developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apogee Therapeutics

Biologics and monoclonal antibody therapeuticsapogeetherapeutics.com

Apogee Therapeutics is a clinical-stage biotechnology company developing half-life extended monoclonal antibodies for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Founded in 2022 as a Paragon Therapeutics spinout, the company went public on NASDAQ in 2024 and is subject to a pending AbbVie acquisition.

What Apogee Therapeutics does

Apogee Therapeutics is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. Founded in 2022 as a spinout from Paragon Therapeutics and led by veterans of BridgeBio, the company went public on NASDAQ under ticker APGE in December 2024 and is headquartered in Waltham, Massachusetts with an additional office in San Francisco. Its pipeline is anchored by zumilokibart (formerly APG777), a subcutaneous half-life extended monoclonal antibody targeting IL-13 that has generated positive Phase 2 Part B 16-week data in moderate-to-severe atopic dermatitis (approximately two-thirds of patients achieving significant skin clearance at 16 weeks) and is also being advanced in asthma and eosinophilic esophagitis. The pipeline additionally includes combination programs APG279 (IL-13 plus OX40L) and APG273 (IL-13 plus TSLP), as well as APG808 targeting IL-4Rα, all leveraging the company's shared antibody engineering platform.

Apogee's underlying technology is an FcRn-mediated half-life extension platform that engineers antibodies to bind better to the neonatal Fc receptor, sparing them from degradation and enabling subcutaneous dosing every three to six months versus the bi-weekly or monthly dosing typical of current standard-of-care biologics such as Dupixent. The company has executed a 'pipeline-in-a-product' strategy, applying the lead asset across multiple I&I indications and pursuing both monotherapy and combination approaches to broaden inflammation coverage. Clinical development currently spans the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

As a pre-revenue biotech, Apogee generates no product sales. Its business model depends on future commercialization through traditional pharmaceutical distribution and field sales teams targeting dermatologists, pulmonologists, and gastroenterologists, supported by a newly appointed Chief Commercial Officer. To date the company has financed operations primarily through capital markets: a $149M Series B (December 2022), a $483M upsized public offering (March 2024), a $345M public offering (October 2025), a $403M public offering (March 2026), and a strategic financing collaboration with Blackstone Life Sciences worth up to $1.3 billion (May 2026). In June 2026, AbbVie announced a definitive agreement to acquire Apogee for approximately $10.9 billion in cash, expected to close in Q3 2026 subject to shareholder and regulatory approvals.

Apogee Therapeutics firmographics

Firmographics
Name
Apogee Therapeutics
Legal name
Apogee Therapeutics, Inc.
Website
https://apogeetherapeutics.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Apogee Therapeutics is a clinical-stage biotechnology company developing half-life extended monoclonal antibodies for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Founded in 2022 as a Paragon Therapeutics spinout, the company went public on NASDAQ in 2024 and is subject to a pending AbbVie acquisition.
Ownership category
akta.pro rank

Apogee Therapeutics industry classification

Industry
Product category
Biologics and monoclonal antibody therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Clinical-stage biotechnology
  • Monoclonal antibody therapeutics
  • Inflammatory disease biologics
  • Atopic dermatitis treatment
  • Antibody engineering platform

Where Apogee Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Apogee Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Biopharmaceutical Development: Clinical-stage biotechnology company with no approved products or revenue. Developing novel biologic therapies for inflammatory and immunology conditions. Revenue will be generated through product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Apogee Therapeutics product offering

Product offering

Core offering

Apogee Therapeutics is developing a pipeline of novel, subcutaneous, half-life extended monoclonal antibody therapeutics targeting well-established immunology and inflammation pathways (IL-13, OX40L, TSLP, IL-4Rα) for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Its lead asset, Zumilokibart (APG777), targets IL-13 with dosing every 3-6 months versus bi-weekly dosing of standard-of-care biologics. The company is also advancing combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), plus APG808 (IL-4Rα).

Product overview

Apogee Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel antibody therapeutics for immunological and inflammatory diseases. The company's core product is Zumilokibart (APG777), a half-life extended monoclonal antibody targeting IL-13, which has completed Phase 2 for atopic dermatitis. The company is pursuing a 'pipeline-in-a-product' strategy with Zumilokibart across multiple indications including atopic dermatitis, asthma, and eosinophilic esophagitis. Additional programs include combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), as well as APG808 (IL-4Rα). All programs leverage advanced antibody engineering to optimize half-life and achieve less frequent dosing compared to existing treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zumilokibart (APG777) Novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of atopic dermatitis (with positive Phase 2 Part B 16-week data), as well as asthma and eosinophilic esophagitis. Designed for subcutaneous dosing every 3 or 6 months versus bi-weekly dosing for current standard-of-care biologics.
  • APG279 Combination therapy comprising APG777 (zumilokibart) plus APG990, designed to address multiple immune signaling intervention points through dual inhibition of IL-13 and OX40L for potential first-in-class combination treatment in atopic dermatitis and other I&I indications.
  • APG273 Combination therapy comprising APG777 (zumilokibart) plus APG333, targeting IL-13 and TSLP for asthma and COPD, designed to address both central and local drivers of obstructive airway disease and potentially break through the efficacy ceiling observed with monotherapies.
  • APG808 Anti-IL-4Rα monoclonal antibody incorporating Apogee's half-life extension technology for the potential treatment of asthma, demonstrating safety and extended half-life in Phase 1 studies.

Quantifiable outcome

  • Phase 2 APEX Part B: Approximately two-thirds of patients achieved significant skin clearance at 16 weeks
  • +2 more outcomes

Companies that use Apogee Therapeutics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Apogee Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Apogee Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AbbViecoreOthers · 22 June 2026AbbVie announced definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash ($135.11 per share). The acquisition aims to strengthen AbbVie's immunology portfolio with Apogee's pipeline including zumilokibart for atopic dermatitis and asthma. Deal expected to close Q3 2026 pending shareholder and regulatory approvals.
  • Paragon TherapeuticscoreStrategic or Co-development Partner · 7 December 2022Apogee acquired drug targets from Paragon Therapeutics at founding. Company spun out from Paragon with access to proprietary antibody engineering technology and targets.

Scale indicators5 records

Recent moves12 records

Expansion highlights5 records

Apogee Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Clinical-stage immunology biotech focused on atopic dermatitis and other inflammatory skin diseases, directly overlapping with Apogee's lead AD indication and the same physician specialty channel.
  • AnaptysBio: Clinical-stage antibody developer focused on immunology and inflammation targets including IL-36, IL-33, and PD-1, with a comparable business model of developing novel mAbs for I&I indications.
  • MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody therapies for inflammatory skin and joint diseases, sharing Apogee's focus on differentiated biologics for I&I indications.
  • Spyre Therapeutics: Clinical-stage biotech developing engineered antibodies for inflammatory bowel disease and other I&I indications, with overlapping leadership and a similar antibody-engineering platform approach.

Emerging players

  • Q32 Bio: Early-stage biotech developing novel biologics for autoimmune and inflammatory diseases, with a similar therapeutic-area focus to Apogee but earlier-stage pipeline assets.
  • Oruka Therapeutics: Clinical-stage immunology company developing long-acting IL-23 antibodies for inflammatory skin diseases, sharing Apogee's half-life extension philosophy and AD indication focus.

Broad incumbents

  • Regeneron Pharmaceuticals: Large biopharma and co-developer of Dupixent (the dominant AD biologic), making it the most direct commercial competitive incumbent to Apogee's lead asset.
  • Eli Lilly: Global biopharma developing lebrikizumab (anti-IL-13) and other immunology assets, a key head-to-head competitor referenced in Apogee's preclinical positioning.
  • AbbVie: Global biopharma and announced acquirer of Apogee; AbbVie's immunology franchise (Skyrizi, Rinvoq, Humira) provides the commercial engine that will deploy zumilokibart post-approval.

Others

  • AbCellera Biologics: Antibody discovery platform company whose technology stack overlaps with Apogee's antibody engineering approach, though AbCellera operates as a discovery engine rather than a clinical developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Apogee Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apogee Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Apogee Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apogee Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apogee Therapeutics

What does Apogee Therapeutics do?

Apogee Therapeutics is developing a pipeline of novel, subcutaneous, half-life extended monoclonal antibody therapeutics targeting well-established immunology and inflammation pathways (IL-13, OX40L, TSLP, IL-4Rα) for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. Its lead asset, Zumilokibart (APG777), targets IL-13 with dosing every 3-6 months versus bi-weekly dosing of standard-of-care biologics. The company is also advancing combination therapies APG279 (IL-13 + OX40L) and APG273 (IL-13 + TSLP), plus APG808 (IL-4Rα).

Is Apogee Therapeutics a public or private company?

Apogee Therapeutics is a public company. It is classified as public and is currently operating.

When was Apogee Therapeutics founded?

Apogee Therapeutics was founded in 2022. It employs 101 to 250 people.

Where is Apogee Therapeutics based?

Apogee Therapeutics is headquartered in San Francisco, United States, in the North America region.

How does Apogee Therapeutics make money?

One revenue line is on record: biopharmaceutical Development.

Who are Apogee Therapeutics's main competitors?

Direct peers on record are Arcutis Biotherapeutics, AnaptysBio, MoonLake Immunotherapeutics and Spyre Therapeutics. Emerging players are Q32 Bio and Oruka Therapeutics. Broad incumbents are Regeneron Pharmaceuticals, Eli Lilly and AbbVie. AbCellera Biologics is listed as an others.

Does Apogee Therapeutics have an API?

No public API is recorded for Apogee Therapeutics.

What industry is Apogee Therapeutics in?

Apogee Therapeutics's product category is Biologics and monoclonal antibody therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate애브비, 면역질환 치료제 성장에 연간 이익 전망 상향 : 네이트 뉴스AbbVie raised its 2026 annual EPS guidance to $13.95-13.99 after reporting Q3 revenue of $17.4B, beating estimates. The increase was driven by growth in immunology drugs Skyrizi and Rinvoq, which offset Humira's decline. The company also plans to acquire Apogee Therapeutics for $10.9B.Seeking AlphaAbbVie: Skyrizi And Rinvoq Keep Delivering As Oncology Gains Momentum (NYSE:ABBV)AbbVie reported 2Q26 revenue of $16.9 billion, up 10.2% year-over-year, with Skyrizi and Rinvoq accounting for 47% of total revenue. The company's oncology segment declined 1.5% to $1.7 billion, but Epcoritamab showed a 51% reduction in disease progression or death in a Phase 3 trial. AbbVie also agreed to acquire Apogee Therapeutics for $10.9 billion.FierceBiotechBiotech builder Paragon imports Apogee's top brass after AbbVie buyoutParagon Labs hired former Apogee Therapeutics executives, including CEO Michael Henderson, after AbbVie's $10.9 billion buyout. Velaris Therapeutics, a Paragon spinout, was acquired by Alaunos Therapeutics, with a $350 million private placement funding the combined company through 2029.pharmaphorumApogee buy delivers eczema trial win for AbbVieAbbVie's zumilokibart achieved statistically significant improvements in EASI-75, EASI-90, and EASI-100 measures versus placebo in a phase 2b atopic dermatitis trial. The company selected the middle dose for phase 3, citing its long half-life and potential as a pipeline-in-a-product. Full data will be presented at the EADV congress in Vienna.Defense WorldApogee Therapeutics Inc. (NASDAQ:APGE) Stock Now Rated “Hold” by Wall Street BrokeragesApogee Therapeutics stock is rated Hold by 19 analysts, with an average price objective of $126.77. The company reported a Q2 loss of $1.14 per share, missing the consensus of $1.07. CEO Michael Henderson sold 20,000 shares, and institutional ownership stands at 79.04%.American Banking and Market NewsApogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Hold” from AnalystsApogee Therapeutics received an average analyst rating of 'Hold' from 19 firms, with a 12-month price target of $126.77. Insiders Carl Dambkowski and CEO Michael Henderson sold shares, and institutional investors own 79.04% of the stock. The company reported a Q2 loss of $1.14 per share, missing estimates.Seeking AlphaSBIO: Big Pharma Needs What This Fund Owns (NYSEARCA:SBIO)The author argues that the ALPS Medical Breakthroughs ETF (SBIO) offers late-stage biotech exposure with a 24-month cash runway requirement, reducing dilution risk. Recent acquisitions of Crinetics and Apogee by Vertex and AbbVie, plus a one-month pullback, make it a satellite position. The author rates it Buy, expecting 15-25% total return over 12 months.Markets DailyEngineers Gate Manager LP Purchases New Shares in Apogee Therapeutics Inc. $APGEEngineers Gate Manager LP acquired a new stake in Apogee Therapeutics during Q2, buying 21,393 shares worth about $2.84 million. The company's CEO Michael Henderson sold 80,000 shares on June 22, and insiders sold 137,400 shares over three months. Analysts rate the stock a Hold with an average price target of $126.77.Yahoo3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)The article recommends three dividend stocks for long-term holding, including AbbVie and Enbridge. AbbVie is a Dividend King with 53 consecutive years of dividend increases, while Enbridge has raised its dividend for 31 years and offers a 5.6% yield. AbbVie also plans to acquire Apogee Therapeutics for $10.9 billion.Seeking AlphaAbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (ABBV)AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, expanding its pipeline in immunology, oncology, neuroscience, and aesthetics. Q2 results beat expectations, driven by Skyrizi and Rinvoq, with a $292 price target cited. Risks include competition, clinical trial outcomes, and balance sheet monitoring.